Description: TRZ-10 (studied as Tirzepatide) is a synthetic research peptide often examined for its dual agonist activity at GIP and GLP-1 receptors. In research settings, tirzepatide peptide has been studied for its potential applications in metabolic and endocrine pathways. This tirzepatide research peptide is provided as a freeze-dried (lyophilized) powder in a 10 mg sealed vial, suitable for controlled laboratory environments. Researchers seeking to buy tirzepatide peptide benefits can expect >99% purity, verified by HPLC testing.
Product Details:
• Compound: TRZ-10 (studied as Tirzepatide)
• Form: Lyophilized powder
• Amount: 10mg per vial
• Appearance: White/off-white powder
• Purity: >99% (HPLC Verified)
• Molecular Formula: C225H348N48O68
• Storage: Store at -20°C in a dry, dark place
Intended Use:
This compound is intended for laboratory research use only. It is not intended for human consumption, medical, or diagnostic purposes.
Related Research Studies:
-
“Tirzepatide is an imbalanced and biased dual GIP and GLP‑1 receptor agonist” (JCI Insight) — Investigates how tirzepatide preferentially binds GIP receptors and activates GLP‑1 receptor signaling in ways that may enhance insulin secretion.
-
“Tirzepatide Once Weekly for the Treatment of Obesity” (NEJM) — Demonstrates that, in clinical trials, weekly tirzepatide dosing produces significant reductions in body weight over time compared to placebo.
Findings:
Research on tirzepatide reveals a notable biased agonist profile, where the compound preferentially engages GIP receptors over GLP‑1 receptors and favors cAMP signaling—potentially boosting insulin secretion more effectively. Additionally, clinical data shows that weekly tirzepatide dosing can produce dramatic reductions in body weight in obesity studies, with effects sustained over extended periods .
Related Links:
